Program Update on Sierra Oncology's Next Generation DNA Damage Response (DDR) Therapies

The event will feature Sierra Oncology, who will present a strategic update on the development programs for its two DDR drug candidates: SRA737 and SRA141. The company will be joined by Dr. Udai Banerji, Chief Investigator for Sierra’s ongoing SRA737 Phase 1/2 clinical studies, and Dr. Alan D’Andrea, a member of Sierra’s DDR Advisory Committee.